
Please try another search
Investing.com - AbbVie (NYSE:ABBV) reported third quarter earnings that beat analysts' expectations on Friday and revenue that topped forecasts.
The firm reported earnings per share of $2.33 on revenue of $8.48B. Analysts polled by Investing.com anticipated EPS of $2.3 on revenue of $8.38B. That compared to EPS of $2.14 on revenue of $8.24B in the same period a year earlier. The company had reported EPS of $2.26 on revenue of $8.26B in the previous quarter.
AbbVie shares lost 0.69% to trade at $79.00 in pre-market trade following the report.
On October 15, J&J reported third quarter EPS of $2.12 on revenue of $20.73B, compared to forecasts of EPS of $2.01 on revenue of $20.08B.
Merck&Co earnings beat analysts' expectations on Tuesday, with third quarter EPS of $1.51 on revenue of $12.4B. Investing.com analysts expected EPS of $1.24 on revenue of $11.65B
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.